INTRODUCTION
• The total expenditure on health care in the United States is increasing at the rate of 5.5% in 2015, which is much higher than most of the OECD countries. However, Americans saw a even faster growth of its prescription drug cost, which showed a rate of 10.9% from 2015 to 2016.
• One strategy to curb the increasing cost is to encourage using more generic drug. Now about 75-90% of the total prescription dispensed are generics, both in commercial health plans and publicly funded health plans, such as Medicare.
• However the high overall generic utilization may mask the variation among subgroups. In our previous study, we found wide variation of the generic utilization between drug classes and plan types (i.e., Medicare Advantage Prescription Drug Plans, and stand-alone prescription drug plans). Presumably, the rate may also vary among people with different health status.
• Elderly people with more than one chronic conditions usually take a substantial number of drug and thus have a strong motivation to use generic alternatives in order to reduce the overall out-of-pocket spending. But there are also studies showed that people have persistent perception that generics are inferior to the branded ones, and the price elasticity of branded drug is less than for generics. This indicates that people may not be willing to switch from branded to generics even the latter is cheaper. Other foundational theoretical work and some empirical studies, also suggest that those with higher morbidity levels are less responsive to copayment increases than their healthier counterparts. However these studies didn't tell us how or whether the generic share of the overall drug mix changes with increasing copayments, particularly as the level of patient's mobility changes. 
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• This study provides preliminary information on the association between generic drug utilization and health status. From the regression results, we see a positive association between the two variables. After adjusting for age, gender, dual eligibility status, out-of-pocket spending and the plan type the beneficiary was enrolled in, the generic share of the beneficiary's total prescription went up a small percent if the beneficiary has one more chronic condition. While the magnitude is small, it does show a statistically significant effect.
• There are several limitations in this study which can be addressed in future studies. First, while the measurement of chronic conditions were accurate and standard, it wasn't weight-adjusted in the regression model. But doing the weight-adjusted way makes more sense if we wanted to be specific about the kind of chronic disease. Second, The mix of generic and branded can vary widely across different drug classes thus the availability of generic alternatives differ among different classes. Third, although the model adjusted for patient out-of-pocket cost and plan types which differ inherently in their utilization management, it didn't account for copay, which should be included in the future.
• The study finds a positive association between generic drug use and the number of comorbidity. However the magnitude of the effect needs to be further studied.
OBJECTIVE
• To study the association between use of generic drug and comorbidity in the elderly population. 
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